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Abstract
Sandhoff disease (SD) is a lysosomal disorder caused by mutations in the HEXB gene. To date, 43 mutations of HEXB have
been described, including 3 large deletions. Here, we have characterized 14 unrelated SD patients and developed a
Multiplex Ligation-dependent Probe Amplification (MLPA) assay to investigate the presence of large HEXB deletions. Overall,
we identified 16 alleles, 9 of which were novel, including 4 sequence variation leading to aminoacid changes [c.626C.T
(p.T209I), c.634C.A (p.H212N), c.926G.T (p.C309F), c.1451G.A (p.G484E)] 3 intronic mutations (c.1082+5G.A,
c.1242+1G.A, c.1169+5G.A), 1 nonsense mutation c.146C.A (p.S49X) and 1 small in-frame deletion c.1260_1265de-
lAGTTGA (p.V421_E422del). Using the new MLPA assay, 2 previously described deletions were identified. In vitro expression
studies showed that proteins bearing aminoacid changes p.T209I and p.G484E presented a very low or absent activity, while
proteins bearing the p.H212N and p.C309F changes retained a significant residual activity. The detrimental effect of the 3
novel intronic mutations on the HEXB mRNA processing was demonstrated using a minigene assay. Unprecedentedly,
minigene studies revealed the presence of a novel alternative spliced HEXB mRNA variant also present in normal cells. In
conclusion, we provided new insights into the molecular basis of SD and validated an MLPA assay for detecting large HEXB
deletions.
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Introduction
Sandhoff disease (SD) [MIM:268800] is a rare neurodegener-
ative disorder resulting from the inability of the ß-hexosaminidase
[Hex; EC: 3.2.1.52] to cleave the terminal N-acetylhexosamine
residues from GM2 ganglioside [1]. Two major Hex isoenzymes
exist: HexA, a heterodimer composed of a/ß subunits and HexB,
a homodimer composed of ß subunits. In vivo, only Hex A
isoenzyme is capable of degrading the GM2 ganglioside in a
complex with the cofactor GM2 activator protein.
Alpha and beta subunits are encoded by the HEXA
(MIM:606869) and HEXB (MIM:606873) genes, respectively.
The GM2A activator protein is encoded by GM2A gene (MIM:
613109).
Mutations affecting HEXA, HEXB or GM2A genes result in a
group of recessive disorders called GM2 gangliosidoses, charac-
terized by the accumulation of GM2 ganglioside [1,2].
Sandhoff disease (SD) results from mutations of the HEXB gene.
Therefore, both HexA and HexB isoenzyme activities are reduced
or absent.
The clinical phenotype varies widely from the infantile form,
characterized by the early onset of a rapidly progressive
neurodegenerative disease, leading to dead before the fourth year
of life, to the later onset forms, a progressive neurological
condition compatible with survival into childhood (subacute form)
or long survival (chronic form) [1].
HEXB gene, mapped to chromosome 5q13 (GeneBank acces-
sion number NM_000521), spans 35–40 Kb and contains 14
exons. Up to date, only 43 HEXB mutations have been reported
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including the large common deletion of 16 kb [Human Gene
Mutation Database (http://www.hgmd.org) [3]. This latter
deletion, accounting for about 27% of the SD alleles among
various ethnic groups [4,5] has never been identified in Italian SD
patients.
We have previously reported the study of HEXB gene in 12
unrelated SD patients [6]. Here, we report the molecular
characterization of the HEXB defect in a further 14 SD unrelated
patients with different geographical/ethnic background. This
study comprises the functional analysis of 9 new sequence
variations identified in the HEXB gene, including 5 missense (4
novel and 1 previously described) and 3 splicing mutations. In
addition to the conventional methods, a Multiplex Ligation
dependent Probe Amplification (MLPA) assay for copy number
analysis of the 14 exons of HEXB gene has been developed to
detect possible large gene deletions.
Methods
The study was approved by the Ethic Committee of the
University Hospital ‘‘Santa Maria della Misericordia’’, the
Institutional Ethics Committee for Health Research, CIEIS,
Children’s Hospital, San Roque’s Hospital and Rawson’s Hospi-
tal, Co´rdoba-Argentina and the Ethic Committee of the University
of Sao Paulo. Written consent was obtained from subjects or
carers/guardians on the behalf of the minors involved in the study.
Patients
Fourteen unrelated patients affected by SD with different
geographical/ethnic background were included in this study. The
diagnosis was suspected on the presence of neurological symptoms
and was confirmed by the demonstration of reduced or absent
total Hex activity in plasma, peripheral white blood cells or
cultured fibroblasts. Four patients were of Italian origin, 5 were
Argentineans, 2 Brazilians, 1 Turkish, 1 Bulgarian and 1 Chinese.
Mutational Analysis of HEXB Gene
Genomic DNA was extracted from peripheral blood leukocytes
or cultured fibroblasts with Imp DNA blood Mini Kit (Qiagen
GmbH, Hilden, Germany). The exonic and flanking intronic
sequences of the HEXB gene were amplified by PCR and analyzed
by automated sequencing (ABI Prism 3500xl genetic analyzer) as
previously reported [6]. Putative mutations were confirmed by
sequencing duplicate PCR products and by the DNA analysis
from parents and relatives whenever possible.
Multiplex Ligation-dependent Probe Amplification
(MLPA) Analysis of HEXB Gene
A set of 17 synthetic probes for MLPA analysis of HEXB gene
was developed according to the guidelines available at http://
www.mrc-holland.com. Thirty four gene-specific oligonucleotides
were used to amplify and to detect 17 different gene-specific
signals: 14 were exon-HEXB specific, while other3, not related to
HEXB gene and specific for alpha-centractin (ACTR1a), actin
filament-associated protein (AFAP) and albumin (ALB), were used
as control for copy number variation (). Primers are listed in Table
S1. MLPA analysis was carried out as described by Schouten et al
[7]. Briefly, 50 ng of DNA in a volume of 4,5 ml were denatured
for 5 min at 98uC. 1.5 ml of salt solution (1.5 M KCl, 300 mM
Tris-HCl pH 8.5, 1 mM EDTA) and 2 ml of probe mix (1–8 fmol
of each synthetic probe oligonucleotide) were added and allowed
to hybridize with the DNA target at 60uC for 16 h. Ligation of
annealed probes was performed in a final volume of 40 ml
obtained by adding 32 ml of ligation buffer (2,6 mM MgCl2,
5 mM Tris-HCl pH 8.5, 0.013% Triton X-100), 0.2 mM
NAD+(BioLabs, Milan, Italy) and 0.2 U of the enzyme Ligase-
65 (MRC-Holland, Milan, Italy). The ligation mix was incubated
for 15 min at 54uC. The Ligase-65 was inactivated by heating at
98uC for 5 min. PCR reaction was carried out in a mixture
containing 5 ml of ligation products, 1.25 U AmpliTaq Gold
(Applied Biosystems, Warrington, UK), the enzyme buffer (Tris-
HCl pH8.3, 1.5 mM MgCl2, 50 mM KCl), 200 nM of forward
and reverse universal primers and 200 mM of dNTPs mix
(Invitrogen, Carlsbad, CA, USA) in a final volume of 25 ml.
PCR was carried out under the following conditions: 95uC for
1 min, followed by 35 cycles of 30 s at 95uC, 30 s at 60uC and
1 min at 72uC. A final extension step was programmed for 20 min
at 72uC.
Amplification products were identified and quantified by
capillary electrophoresis on an ABI Prism 3500xl genetic analyser,
using Genescan analysis software (version 4.1) (Applied Biosys-
tems, Warrington, UK).
The relative quantification of HEXB copy number was obtained
by dividing the height of each gene-specific peak by the sum of the
3 endogenous control peaks present in 2 copies per diploid
genome. This ratio was then compared to the average ratio
obtained from 8 control samples having each 2 HEXB gene copies.
A ratio between 0.75 and 1.25 corresponds to 2 HEXB copy
number while a ratio between 0.25 and 0.75 corresponds to 1
HEXB copy number.
In Silico Analysis
To predict the potential effect of the novel mutant alleles on
splicing process, the following programs were used: Maximum
Entropy (ME) available at http://genes.mit.edu/burgelab/
maxent/Xmaxentscan_scoreseq_acc.html and Neural Network
(NN) available at http://www.fruitfly.org/seq_tools/splice.html.
Protein Visualization and Structural Analysis
For modelling the HEXB missense mutations, we used the three
dimensional atomic coordinates available at the Protein Data Bank
(PDB) of the apo-protein and of its form bound to a known
inhibitor [8] (PDB codes 1NOU and 1NOW). Visual inspection
and graphical representations were then carried out using the
programs Coot [9] and Chimera [10], respectively.
HEXB Missense Constructs
To assess the potential impact of 5 missense HEXB sequence
variations on Hex activity we performed in vitro expression
experiments. The complete cDNA of HEXB was cloned in the
pcDNA4/myc-His (Invitrogen, Carlsbad, CA, USA) expression
vector (pcDNA4/mycHEXBN). Mutations p.T209I (pcDNA4/
mycHEXB209), p.N212H (pcDNA4/mycHEXB212), p.C309F
(pcDNA4/mycHEXB309), p.G484E (pcDNA4/mycHEXB484)
and p.R533C (pcDNA4/mycHEXB533) were introduced in the
pcDNA4/mycHEXBN construct by site directed mutagenesis
using the QuikChange Site-Directed Mutagenesis Kit (Stratagene,
Cedar Creek, TX, USA) according to the manufacturer’s
instructions. Primers are listed in Table S2.
Minigene Constructs
To evaluate the effect of the intronic HEXB mutations
c.1082+5G.A, c.1169+5G.A and c.1242+1G.A on exon 8, 9
and 10 expression, normal minigenes (p.HEXB7-9 N, p.HEXB8-9
N and p.HEXB9-11 N) were prepared by cloning the genomic
sequences from exons 7 to 9, 8 to10 and 9 to 11 of HEXB,
respectively, in pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). PCR
Functional Analysis of New HEXB Sequence Variants
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amplification was performed using primers Minigene HEXB 7-8-9
Fw-Rv, Minigene HEXB 8-9-10 Fw-Rv and Minigene HEXB 9-
10-11 Fw-Rv, listed in Table S2. The forward and reverse primers
used for the amplification carried the NotI and Xho restriction site,
respectively.
Mutant minigenes, p.HEXB7-9 mut, p.HEXB8-9 mut and
p.HEXB9-11 mut carrying the sequences bearing the
c.1082+5G.A, c.1169+5G.A and c.1242+1G.A substitutions,
respectively, were prepared by site directed mutagenesis using the
QuikChange Site-Directed Mutagenesis Kit (Stratagene, Cedar
Creek, TX, USA) according to the manufacturer’s instructions.
Primers are listed in Table S2.
Cell Culture and Transient Transfection
Human Hek293 [11] cells were grown in DMEM high glucose
medium (Gibco, Paisley, UK) supplemented with 10% (v/v) foetal
bovine serum, 50 mg/ml penicillin/streptomycin and 2 mM L-
glutamine (Gibco, Paisley, UK). Cells were maintained at 37uC in
a humidified atmosphere enriched with 5% (v/v) CO2 and
transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) using 4 mg of total plasmid DNA Endofree purified (Qiagen
GmbH, Hilden, Germany) following manufacturer’s instructions.
To normalize transfection efficiency between experiments, cells
were transiently cotransfected with 2 mg of a construct bearing the
GFP cDNA, and the fluorescence was measured by FACS
analysis.
Minigene Splicing Assay
Hek293 cells were transfected with the normal and mutant
minigene constructs. Total RNA was extracted after 48 h using
TRIzol reagent (Gibco, Paisley, UK) and analyzed by RT-PCR.
Reverse transcription was performed using random primers; the
PCR reaction was carried out with a forward vector-specific
primer (59-AATACGACTCACTATAGGG) and the reverse
primers Minigene HEXB 7-8-9 Rv, Minigene HEXB 8-9-10 Rv
and Minigene HEXB 9-10-11 Rv (Table S2). PCR products were
resolved in a 1% agarose gel and sequenced.
Immunoprecipitation and Enzyme Activity Assay
Hek293 cells were transfected with normal and mutant myc
tagged constructs. Forty eight hours after transfection, cells were
washed with phosphate-buffered saline (PBS), harvested and
sonicated. Protein concentration of the samples was determined
by the Bradford method. Solid-state immunoprecipitation assay
for Hex was performed based on the previous report [12]. Briefly,
140 ml of cell lysate corresponding to 20 mg of protein was rotated
at 4uC overnight with 30 ml of protein A Sepharose beads
(Amersham Pharmacia Biothech, NJ) and 1 ml of anti-myc mouse
monoclonal antibody (Cell signalling, Hitchin, UK).
After centrifugation for 15 min at 12,000 g, precipitated beads
were washed twice with cold PBS and assayed directly for
determining Hex activity. Total Hex activity was measured using
the fluorogenic substrate 4-methyllumbelliferyl-2-acetamido-2-
deoxy-b-Dglucopyranoside (4MUG; Sigma, St. Louis, MO,
USA). Total activity was estimated by incubation at 37uC for
15 min in the presence of 3 mM of 4MUG and 0.1 M of citrate–
phosphate buffer (pH 4.6) in a total volume of 300 ml. Reactions
were stopped by adding 1.5 ml of 0.2 M glycine–NaOH buffer
(pH 10.6). Fluorescence excitation was conducted at 365 nm
wavelength and emission was determined at 495 nm. The residual
enzymatic activity was expressed as percentage of the values
obtained in cells transfected with the normal construct.
Mutation Nomenclature
All mutations are described according to the recommended
nomenclature [13,14] http://www.hgvs.org/mutnomen. Nucleo-
tide numbers are derived from cDNA sequences (GenBank HEXB
cDNA:NM_000521).
Statistical Analysis
Statistical analysis was performed using Student’s t test analysis.
P,0.05 was considered as statistically significant.
Results
Molecular Analysis of HEXB Gene
The molecular analysis of HEXB gene was performed in 14
patients affected by SD.
Table 1 shows the geographic/ethnic background, age at onset,
age at last observation, total Hex activities and the 13 different
genotypes identified in this series.
Thirteen patients presented with the severe infantile form of SD
characterized by early onset, between 4–12 months of age, while
one patient (SD1) presented with the subacute form of the disease.
At diagnosis, all patients presented with hypotonia, psychomotor
skills regression and the presence of a cherry-red spot on fundus
examination, except for patient SD14 who did not have this last
ocular sign. Startle reaction was reported in 11 patients (SD1 to
SD11). Patients SD3, SD5-SD8, SD10- SD12 and SD14
developed seizures. Ten infantile patients died before the fourth
year of life, while 3 are still alive; patient SD1, with the subacute
form died at the age of 10 years (Table 1).
Most patients were of Italian and Argentinean origins, except
patients SD12, SD13 and SD 14 who were of Turkish, Bulgarian
and Chinese ancestry, respectively, and patients SD10 and SD11
who were of Brazilian ancestry. Parents of patients SD11 and
SD14 were consanguineous. Argentinean patients SD5, SD7 and
SD8 were from a geographic area in Cordoba characterized by a
high SD incidence [15], while SD6 and SD9 were from Buenos
Aires.
Overall, the mutational spectrum of the present series comprises
16 different alleles, including 9 previously unpublished. Among the
novel alleles, 4 were sequence variations resulting in codon
replacements [c.626C.T (p.T209I), c.634C.A (p.H212N),
c.926G.T (p.C309F), c.1451G.A (p.G484E)]; 3 were splice site
alterations (c.1082+5G.A, c.1242+1G.A, c.1169+5G.A), 1 was
a nonsense mutation c.146C.A (p.S49X), and 1 was a small in-
frame deletion c.1260_1265delAGTTGA (p.V421_E422del). One
allele remained unknown. even after MLPA assay.
Detection of Deletions in HEXB Gene through MLPA
Assay
In order to analyze the presence of large deletions of the HEXB
gene non detectable by PCR and sequencing, we developed a
synthetic probe set for multiplex ligation-dependent probe
amplification (MLPA) analysis [7]. After optimizing the probe
specificity for HEXB and references genes, 14 SD patients, 8
normal controls and 2 positive controls carrying two previously
described deletions, c.299+1471_408del2406 (here named as
Del1) [6] and the 16 kb deletion (here named as Del2) [16],
respectively, were analyzed. The c.299+1471_408del2406 has
been reported to remove part of intron 1 and exon 2, while the
16 Kb deletion comprises the promoter region, exons 1–5 and
part of intron 5. The MLPA analysis showed the presence of a
partial HEXB deletion affecting exon 2 in SD1 patient and a
partial HEXB deletion affecting exons 1 to 5 in SD4 patient
(Figure 1), while other SD patients showed a normal pattern (data
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not shown). MLPA results were also confirmed in SD1 and SD4
patients’ parents. PCR and sequencing analysis confirmed the
presence of the c.299+1471_408del2406 deletion in the patient
SD1 and the 16 Kb deletion in the patient SD4 (data not shown).
Characterization of the Novel Missense Sequence
Variants
Four novel missense variations were found in 6 SD families:
c.626C.T (p.T209I), c.634C.A (p.H212N), c.926G.T
(p.C309F), c.1451G.A (p.G484E).
The impact of these 4 aminoacid changes on protein function
was evaluated by in vitro expression of mutant constructs in Hek293
cells and the analysis of the expressed Hex activity after
immunoprecipitation. As a negative control, Hek293 cells were
transfected with empty pcDNA4/myc-His vector. In addition, the
mutation p.R533C (c.1597C.T), although no longer novel since
it was reported during the preparation of the present study by
Kaya et al [17], was also included in the analysis.
Since untransfeced Hek293 cells showed a quite high level of
endogenous Hex activity, we transfected them with constructs
designed to generate myc tagged normal and mutant HexB
proteins, which could be easily separated from the endogenous
HexB by immunoprecipitation with an anti-myc antibody.
Transfection of Hek293 cells with the normal HEXB cDNA
resulted in an 8 to 10-fold increase of total Hex activity measured
on the immunoprecipitated complex, compared to the activity of
Hek293 cells transfected with the empty vector. No changes in the
viability of transfected cells were observed. As shown in Figure 2,
the in vitro residual activity of the 5 missense mutants was
significantly lower than the activity of the normal protein.
However, while p.T209I, p.G484E and p.R533C mutant variants
showed a very low or absent Hex activity as compared to the
normal protein, proteins bearing the p.H212N and the p.C309F
aminoacid changes retained a residual activity of 59 and 36% of
normal, respectively (Figure 2). In the light of these data, further
experiments were planned to exclude the potential occurrence of
additionally intronic mutations affecting the mRNA splicing
process. In the case of p.C309F, found in heterozygosis with the
severe c.1303_1304delGT (p.R435fsX20) mutation [18], the RT-
PCR analysis of the HEXB mRNA in fibroblasts from patient SD2
showed the presence of a single product, which was confirmed by
sequencing analysis as corresponding to the normal spliced HEXB
transcript carrying the p.C309F mutation. This excluded the
potential coexistence of other mutations on the same allele.
Unfortunately, the mRNA of the patient SD12, homozygous for
p.H212N, was not available to exclude the potential occurrence of
a second in cis mutation. Although biochemical data were
suggestive of Sandhoff disease, other clinical forms of GM2
Gangliosidosis (Tay-Sachs and GM2-gangliosidosis, AB variant)
were considered and HEXA and GM2A genes were analysed,
excluding a potential clinical misdiagnosis.
To shed further light on the possible consequences of these
aminoacid changes at protein level, we visualized the atomic
structure of HexB determined by X-ray Crystallography (Figure 3).
p.T209I: the structural analysis of the mutation predicted that
the replacement of a hydrophilic residue (T) with the hydrophobic
isoleucine (I), occurring in the proximity of a residue (R211) know
to be involved in substrate binding, may lead to an impairment of
the enzyme activity.
p.H212N: although the H212 residue is exposed on the protein
surface in the dimmer interface very close to the substrate binding
site, the replacement with asparagine might be conservative as
both residues, histidine (H) and asparagine (N), have a similar size,
both are polar and protonated at acidic pH.
p.C309F: cysteina 309 is involved in a disulphide bond with its
partner C360, which keeps two chains, A and B of b subunit
tightly bound after the cleavage of the protein precursor. The
mutation p.C309F would abrogate the formation of the disulphide
Table 1. Genotypes of SD patients analyzed in this study.
Patient Origin
Age at
onset
Age at
observation
Total Hex activity1
(% of normal
controls) Genotype*
SD1 Italy 18 m 10 y+ 2.8 [c.626C.T(p.T209I)]+ [c.299+1471_408del2406]
SD2 Italy 4 m 3y9m+ 11.5 [c.1303_1304delGT(p.R435fsX20)]+ [c.926G.T(p.C309F)]
SD3 Italy 6 m 2y6m+ 2.6 [c.1451G.A(p.G484E)]+[?]
SD4 Italy 6 m 2y3m+ 3.1 [c.448A.C(p.T150P)]+ [16Kbdel]
SD5 Argentine 4 m 2y8m+ 1.1 [c.445+1G.A (r.0)]+[c.1451G.A(p.G484E)]
SD6 Argentine 4–6 m 2y11m+ 1.3 [c.445+1G.A (r.0)]+[c.1597C.T(p.R533C)]
SD7 Argentine 4–6 m 3y4m+ 4.2 [c.445+1G.A (r.0)]+[c.1242+1G.A (p.K390_K414delfsX7)]
SD8 Argentine 4–5 m 3y+ ND [c.445+1G.A (r.0)]+[c.1242+1G.A (p.K390_K414delfsX7)]
SD9 Argentine 4–5 m 3y+ ND [c.1082+5G.A(p.G301_W361delfsX10)]+
[c.1601G.A(p.C534Y)]
SD10 Brazil 12 m 4y2m 2.8 [c.1169+5G.A(p.E362_K390del)]+ [c.448A.C(p.T150P)]
SD11** Brazil 8 m 3y9m 8.1 [c.634C.A(p.H212N)]+ [c.634C.A(p.H212N)]
SD12 Turkey 4m 2y + NA [c.1597C.T(p.R533C)]+ [c.1597C.T(p.R533C)]
SD13 Bulgaria 9 m 1y3m 1.6 [c.146C.A(p.S49X)]+ [c.146C.A(p.S49X)]
SD14 China 12 m 2y 15 [c.1260_1265delAGTTGA(p.V421_E422del)]+
[c.1260_1265delAGTTGA(p.V421_E422del)]
ND: not detectable; NA: not available. Novel mutations are indicated in bold, *RefSeq cDNA:NM_000521. For cDNA numbering +1 corresponds to the A of the first ATG
translation initiation codon. RefSeq protein: NP_000512.1. **indicates parents’ consanguinity. m: month; y: years; +deceased; 1Owing to the use of different assay
methods and tissue samples, total Hex activity values are expressed as a percentage of average control values.
doi:10.1371/journal.pone.0041516.t001
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bridge. However, hydrogen bond interactions, which occur among
the strands within the protein beta-sheets, may hold chains A and
B together, even in the absence of the disulphide bridge.p.G484E:
this change, introducing a negatively charged glutamate (E),
approximately 10A from the substrate binding site region, was
predicted to interfere with the plasticity of the protein main chain
and to alter the local electrostatic parameters.
Finally, structural analysis predicted that the p.R533C change,
affecting a residue (R533) involved in the dimerization, might
severely disturb the dimer formation. In addition, the novel C533
may form a disulphide bound with C551 (normally involved in a
disulphide bound with C534), leading to a severe misfolding of the
C terminal loop of the protein.
Characterization of the Three Novel Splicing Mutations
The possible effect of the new intronic mutations
c.1082+5G.A, c.1169+5G.A and c.1242+1G.A, on the
mRNA splicing process was first evaluated in silico using two
splicing prediction programs, NN splice and MES. Both programs
clearly predicted that the mutated sequences would (i) no longer be
recognized as splicing sites when the alteration involved one of the
invariant motif of the classical consensus sequences
(c.1242+1G.A) or (ii) cause a reduction in the strength of the
Figure 1. MLPA analysis of SD1 and SD4 patients. Panels A–C: Capillary electrophoresis profile of the MLPA analysis performed in a normal
control (panel A) and patients SD4 (panel B) and SD1 (panel C). Each peak corresponds to the amplification of a probe specific for each exon of HEXB
gene (numbered 1 to 14) and for 3 different reference genes (R1, R2, R3). Arrows indicate the peaks corresponding to the HEXB exons deleted in SD1
and SD4 patients. Panel D) Relative quantification of HEXB copy number was obtained by dividing the height of each gene-specific peak by the sum
of the heights of 3 reference gene peaks. This ratio was then compared to the average ratio obtained from 8 control samples having each 2 HEXB
gene copies. A ratio between 0.75 and 1.25 corresponds to 2 HEXB copy number while a ratio between 0.25 and 0.75 corresponds to 1 HEXB copy
number.
doi:10.1371/journal.pone.0041516.g001
Figure 2. In vitro functional analysis of new missense sequence
variations. Total Hex activity after immunoprecipitation with anti-myc
antibody of HEXB missense mutant proteins expressed in Hek293cells.
Results are expressed as the percentage of total Hex activity detected
after immunoprecipitation of myc-tagged normal HEXB expressed in
Hek293cells (N). The data are shown as mean6SD of three different
experiments, each performed in duplicate. *p,0.05.
doi:10.1371/journal.pone.0041516.g002
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splice site when mutations were located in non-canonically
invariant splice site motifs (c.1082+5G.A and c.1169+5G.A)
(Table 2).
Since the fibroblasts from patients SD7, SD8, SD9, SD10 were
not available, we used a minigene assay to study the effect of the
c.1082+5G.A, c.1169+5G.A and c.1242+1G.A mutations on
the mRNA splicing process. Normal and mutant minigenes were
transfected into Hek293 cells and total RNAs were reverse
transcribed to cDNAs. Specific PCR analysis showed the
amplification of PCR products of different length in cells
transfected with normal and mutant HEXB alleles. The identities
of the PCR products were confirmed by sequencing.
As expected, the mutant construct bearing c.1082+5G.A
produced a 181 nt shorter transcript, which lacks exon 8. The
skipping of exon 8 would lead to the shifting in the reading frame
and the generation of a premature stop codon
(p.G301_W361delfsX10) (Figure 4a and b). In the same vein,
the c.1169+5G.A mutation determined the predicted skipping of
87 nt of exon 9, causing the in-frame exclusion of 28 aminoacids
from the mature protein (p.E362_K390del) (Figure 4c and d). The
mutant c.1242+1G.A yielded two different transcripts (Figure 5a):
i) a transcript lacking 73 nt corresponding to the entire sequence of
exon 10, as predicted by in silico analysis, and ii) a transcript
lacking 73 nt of exon 10 and a portion of exon 11 (Figure 5b). In
fact, a cryptic splice site, located 112 nucleotides downstream of
the normal acceptor site of exon 11, obtained a higher score than
the canonical acceptor site when tested with both prediction
programs used in this study (Table 2). The cryptic splice site was
recognized as an acceptor splice site in cells transfected with the
normal minigene construct as well (Figure 5a, b). The recognition
of this cryptic splice site resulted in the exclusion of 112 nt from
the mature transcript. In order to confirm this result in vivo, a RT-
PCR analysis of the HEXB mRNA followed by sequencing of PCR
products was performed on the RNA extracted from normal
fibroblasts. Two mRNA variants were detected: one containing
the entire exon 11 sequence and one lacking the 112 nt of exon
11. This result confirmed the data obtained by the minigene assay
Figure 3. Location of HEXB mutations on the 3D structural model. Chains A and B are drawn as orange and blue ribbons respectively.
Positions of mutations are indicated by arrows and the residues represented by spaced-filled spheres.
doi:10.1371/journal.pone.0041516.g003
Table 2. In silico analysis of novel splicing mutations.
Mutation Prediction programs
NN
Wt score/mut score
ME
Wt score/mut score
c.1082+5G.A 59ss: 8,85/3,23 59ss: 0,91/0,26
c.1169+5G.A 59ss: 9,72/4,06 59ss: 0,94/0,14
c.1242+1G.A 59ss: 9,60/1,42; 39ss:1,32/1,32; Cryptic 39ss: 6,49/6,49 59ss: 1,00/ND; 39ss: ND/ND;
Cryptic 39ss: 0,51/0,51
ND: Not detected; ME: Maximum Entropy; NN: Neural Network.
doi:10.1371/journal.pone.0041516.t002
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and indicates that two different HEXB transcripts, generated by
alternative spicing, are present in normal cells (Fig. 5c).
Discussion
Sandhoff disease is a severe neurodegenerative lysosomal
storage disorder caused by mutations in the HEXB gene. To date,
a total of 43 mutations of HEXB gene have been described as a
cause of SD. In this study, we report the results from the molecular
characterization of 14 SD unrelated patients with different
geographical/ethnic background.
All patients presented with the severe infantile form of the
disease except patient SD1 who had the subacute form of SD. In
spite of this, high residual Hex activity was detected in the severely
affected patients SD2, SD11 and SD14. Residual enzyme activity
has been suggested to be related to clinical outcome in lysosomal
diseases. However in these three patients phenotype and residual
enzyme activity do not seem to correlate.
Several hypotheses could explain these results, including the
concurrence of other genetic and epigenetic factors in influencing
the phenotype [19]. Another underlying cause might be attributed
to increased levels of Hex S, a third b-hexosaminidase isoenzyme
composed of two a subunits (HexS), present in very small amounts
in normal tissues. Indeed, increased levels of HexS have been
previously reported as associated with the absence of beta subunits
[20,21]. Therefore, a small contribution of this isoenzyme to the
residual activity detected in these patients cannot be excluded. In
addition, it should be taken into account that the substrate for
HexA in vivo is the GM2/GM2 activator complex [22]. Thus, it
may also be possible that the mutations present in these patients
lead to the synthesis of a HexA variant which cannot efficiently
bind to the GM2 activator. In this case, the activity against the
synthetic substrate may not reflect the activity in vivo. Finally,
another factor to be considered is that variations in the levels of
residual activity may be found in different tissues. Considering this
hypothesis the clinical course of SD, characterized by a progressive
neurodegeneration, may correlate with the enzymatic activity in
the brain, which may differ from that detected in peripheral
tissues.
In this study, 16 different mutations were identified; most of
them were present in single or few families. The only exception
was represented by the c.445+1G.A (r.0) mutation found in 4 out
of 5 families of Argentinean origin. This mutation has already
been described as the most frequent allele among Argentinean SD
patients [15]. Notably, two Argentinean patients, SD7 and SD8,
coming from a geographic area in Cordoba characterized by a
high incidence of SD [15] carried the same genotype. As a close
relationship was not proved between these families, the common
Figure 4. In vitro functional analysis of mutations c.1082+5G.A and c.1169+5G.A. RT-PCR analysis of the HEXB mRNA in cells transfected
with normal (pcDNA3HEXBN) and minigenes containing mutations c.1082+5G.A (pcDNA3HEX1082) and c.1169+5G.A (pcDNA3HEX1169) (panels A
and C, respectively). MW: 1 kb Plus DNA Ladder. Schematic representation of the effect of the novel mutations on the splicing process (panels B and
D). Sequencing analysis of RT-PCR products showed that the c.1082+5G.A mutation determines the skipping of 178 nt of exon 8 (panel B), whereas
the presence of c.1169+5G.A mutation determines the retention of 87 nt of exon 9 (panel D).
doi:10.1371/journal.pone.0041516.g004
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origin from the same geographically localized area may explain
this result.
During the course of the analysis of the SD4 patient’s family we
noted that the results did not entirely concur among the family
members. More specifically, while the p.T150P mutation was in
apparent homozygosis in the patient, it was absent in one of his
parents. Similarly, the second mutation in patients SD1 and SD3
remained uncharacterized after sequencing the entire coding
region of HEXB gene. Therefore, among the possible underlying
reasons for these findings, we hypothesized the presence of a
deletion in the second allele. In fact, among the HEXB mutations
already published, three large HEXB deletions have been
identified: (i) a 16 kb deletion which removes the promoter region,
the exons 1–5 and part of intron 5 [16], (ii) a 50 kb deletion which
removes 25 kb 59 of the promoter up to intron 6 [23] and (iii) a
2.5 Kb deletion which involves part of intron 1 and exon 2 [6]. In
particular, the 16 kb deletion, accounting for 27% of the SD
mutant alleles, has been reported as the most frequent mutation in
patient affected from SD with different ethnic backgrounds [4,5],
but never identified in Argentinean [15] and Italian [6]
populations.
Hence, we set up a Multiplex Ligation dependent Probe
Amplification (MLPA) assay to ascertain accidental misgenotyping
in our panel of SD patients and to analyze the alleles that
remained uncharacterized after being studied by conventional
techniques.
This experimental approach, based on the simultaneous
determination of copy number variation in a semiquantitative
fashion, was effective in identifying the common large deletion
(16 kb) in an Italian SD patient for the first time and the rare
c.299+1471_408del2406 mutation in another patient of Italian
origin. One allele remained unknown even after MLPA analysis,
suggesting the presence of a deep intronic mutation that may affect
the mRNA splicing process. The analysis of the HEXB mRNA
should be preformed to confirm this hypothesis.
These results confirmed by PCR and sequencing analysis,
allowed us to validate the MLPA assay as a valuable, rapid and
economic method for detecting large deletion in SD patients and
to reduce the risk of misdiagnosis.
Overall, we identified 9 new sequence variations. Among them,
the homozygous nonsense mutation c.146C.A (SD13) was
predicted to introduce the premature stop codon likely leading
to a very short truncated protein (p.S49X), while the always
Figure 5. In vitro functional analysis of mutation c.1242+1G.A and exon 11 splicing analysis in normal fibroblasts. Panel A: RT-PCR
analysis of the HEXB mRNA in cells transfected with normal (pcDNA3HEXBN) and a minigene containing mutation c.1242+1G.A (pcDNA3HEX1242)
MW: 1 kb Plus DNA Ladder. Panel B: Schematic representation of the effect of the novel mutations on the splicing process. Sequencing analysis of RT-
PCR products showed that the presence of c.1242+1G.A mutation determines the skipping of 73 nt of exon 10. In addition the presence of a 39
cryptic splice site (present in both normal and mutant minigenes) determines the skipping of 112 nt in exon 11(denoted as red box) in cells
transfected with both normal and mutant minigenes. Panel C: RT-PCR analysis of the HEXB mRNA in normal fibroblasts. MW: 1 kb Plus DNA Ladder.
doi:10.1371/journal.pone.0041516.g005
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homozygous c.1260_1265delAGTTGA mutation (SD14) resulted
in an in-frame deletion, which determined the absence of two
conserved residues: V421 and E422 (http://www.ensembl.org/).
In addition, structural analysis showed that the deletion of these
two aminoacids within the T419-V423 beta-strand, would displace
the position of the W424, which is important for the correct
substrate orientation.
As report in Figure 2, in vitro functional analysis of the mutant
p.T209I, p.G484E and R533C proteins, showing a very low or
absent Hex activity, clearly demonstrated their pathogenic nature.
The analysis of the possible effect of these residue changes on
protein structure showed that these aminoacid replacements would
cause a severe impairment of protein structure and function.
The functional analysis of proteins carrying the p.H212N and
p.C309F aminoacid changes showed that both retained a quite
high residual activity (Figure 2). Indeed, computational analysis
predicted that the replacement of p.H212N must not lead to
severe structural changes since both aminoacids, histidine (H) and
asparagine (N) are similar in size and polarity and both are
supposed to be protonated at acidic pH. Instead, the results of the
functional and structural analyses did not concur in the case of the
C309F mutation, as this residue change was predicted to abrogate
the formation of the disulphide bridge that keeps two chains (A
and B of b subunit) tightly bound after the cleavage of the protein
precursor. Following these controversial results, a more detailed
examination of the protein structure showed that hydrogen bond
interactions, which occur among the strands within the protein
beta-sheets, may hold chains A and B together. Therefore, it is
likely that, a fraction of the expressed protein could still maintain a
proper folding and be partially active thanks to the hydrogen bond
interactions.
Unexpectedly, the high residual activity retained by proteins
bearing the H212N and C309F changes did not correlate with the
severe clinical phenotype presented by patients (SD11 and SD2).
In particular, the p.H212N change, found at homozygosity in a
severely affected patient born from consanguineous parents,
caused only 41% reduction of Hex activity. Whether this mutation
is in fact deleterious or causes a Hex pseudodeficiency remains
unclear. However, it is worth to point out that the clinical features
presented by the patient are strongly suggestive of a GM2
gangliosidosis and the sequence analysis of the HEXA and GM2A
genes, showing the absence of mutations enabled us to exclude
other clinical forms of GM2 gangliosidosis. In the light of these
data, it is possible to hypothesize the occurrence of a second in cis
mutation causing a severe impairment of mRNA processing and/
or expression. Unfortunately, the patient’s mRNA was not
available to test this hypothesis.
The mutation p.C309F, found in compound heterozygosity
with the severe c.1303_1304delGT (p.R435fsX20) mutation,
retained 36% of activity when expressed in vitro. In this case, the
potential coexistence of other mutations on the same allele
carrying the p.C309F was excluded by the analysis of the HEXB
mRNA extracted from the patient’s fibroblasts. These findings
suggest that factors other than the patients’ genotype might
influence the severity of the disease. Discrepancies between the in
vitro residual enzymatic activity and the clinical phenotype have
been described in lysosomal storage disorders including SD
[12,24–27]. In particular, such miscorrelation has been reported
by Yoshizawa et al [12] in a late onset SD phenotype found to be
associated with to the HEXB mutant p.R533H, which was
completely inactive when expressed in vitro.
Indeed, these discrepancies may be caused by the fact that the
results obtained in vitro do not necessarily reflect in vivo alterations,
when the mutated proteins are expressed at a certain level, in a
particular cell type and organelle interacting with other proteins.
However, for most enzymes it is impractical to measure the
activity in vivo and in any case it is not possible to determine the
effect of a single mutation in heterozygous patients. Therefore, we
have to rely on in vitro assays, keeping in mind their limitations.
Finally, minigene studies performed to demonstrated the impact
of the 3 new intronic mutations (c.1082+5G.A, c.1169+5G.A
and c.1242+1G.A) upon the mRNA splicing process, revealed
that a novel alternative spliced HEXB mRNA variant was also
present in normal control cells, owing to the recognition of a
cryptic splice site within exon 11. This finding suggests caution in
the interpretation of results potentially leading to a molecular
misdiagnosis.
In conclusion, our results confirmed the remarkable heteroge-
neity of the mutational spectrum of the HEXB gene and provided
new insights into the molecular basis of SD. In addition, the
present study stresses the importance of investigating copy number
changes in order to avoid misinterpretation of the molecular
testing results.
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